MELANOMA

This early-stage study tested a new cancer drug called PF-07820435, both alone and combined with an existing immunotherapy drug (sasanlimab), in people with advanced solid tumors. The main goals were to find safe doses and look for early signs that the treatment might help shrink…

This study tested if adding a new drug called CMP-001, injected directly into a tumor, could improve the effectiveness of the standard immunotherapy nivolumab for people with advanced melanoma that cannot be removed by surgery. It compared the combination treatment to nivolumab a…

This early-stage study tested the safety and determined the right dosage of a new drug called PF-08046031 for adults with advanced melanoma and other solid tumors that have spread and have no other approved treatment options. The main goal was to identify side effects and see how…

This early-phase study tested a new treatment called BT-001, which is injected directly into tumors. It was given alone and combined with an existing immunotherapy drug (pembrolizumab) to people with advanced cancers that had spread. The main goals were to find a safe dose and se…

This study tested whether the drug imatinib could help control metastatic ocular melanoma, a serious cancer that starts in the eye and spreads. It involved 13 adult patients whose cancer had spread to other parts of their body. The main goal was to see if the treatment could stop…

This study tested whether a combination of two drugs, pembrolizumab and lenvatinib, could shrink tumors in the brain for patients with melanoma or kidney cancer that had spread there. The trial was for patients whose cancer had worsened despite previous immunotherapy. The main go…

This study tested a new, experimental drug called APX005M, which was injected directly into tumors. It was combined with an approved immunotherapy drug (pembrolizumab) given by IV. The main goals were to find a safe dose and see if the combination could help control advanced mela…

This early-stage clinical trial tested a new drug called DCC-3084, both alone and combined with other cancer therapies, for people with advanced solid tumors driven by specific genetic mutations. The study aimed to find a safe dose and see if the treatment could shrink tumors in …

This early-phase study tested the safety and best dose of an immunotherapy drug called STI-3031. The drug was delivered directly into the lymph vessels or nodes of a single limb using a special device, aiming to treat melanoma that had spread locally. The goal was to see if this …

This was an early-stage study testing a new drug called BDC-3042, both by itself and combined with an existing immunotherapy (cemiplimab), in people with advanced cancers that had stopped responding to standard treatments. The main goals were to find safe doses and see if the tre…

This study tested two different combinations of cancer drugs for people with advanced melanoma that had a specific genetic change (BRAF mutation) and had stopped responding to a common first-line immunotherapy. Participants received either a three-drug combination (encorafenib, b…

This study tested whether a two-drug immunotherapy combination works better than a single drug to prevent melanoma from returning after it has been surgically removed. It involved over 1,000 patients whose stage III or IV melanoma was completely cut out. The goal was to see which…

This study tested whether the drug niraparib could help control advanced solid tumors in patients whose cancer has a specific genetic change called a PALB2 mutation. It involved 22 adults with various cancers (like breast, lung, or pancreatic) that had spread or were locally adva…

This early-stage study aimed to find a safe dose of a new drug called HFB301001 for adults with advanced cancers that had stopped responding to standard treatments. It involved 31 patients with cancers like sarcoma, kidney, liver, and melanoma. The trial was designed to test incr…

This large, late-stage trial aimed to see if adding a new immunotherapy drug (spartalizumab) to two existing targeted drugs (dabrafenib and trametinib) could better control advanced melanoma with a specific BRAF gene mutation. It involved 568 previously untreated patients whose c…

This study tested whether taking an oral pill containing specific gut bacteria (EDP1503) could improve the effectiveness of a standard immunotherapy drug (pembrolizumab) for people with advanced melanoma. It involved two groups: patients new to this type of immunotherapy and thos…

This early-phase study tested the safety and initial effectiveness of a new drug called modakafusp alfa, both alone and combined with an existing immunotherapy (pembrolizumab), in adults with advanced solid tumors or melanoma. The main goals were to find a safe dose and check for…

This study tested an experimental drug called vobramitamab duocarmazine in people with advanced prostate cancer that had stopped responding to hormone therapy, as well as other solid tumors. The trial aimed to see if the drug could slow cancer growth and shrink tumors. The study …

This study tested a new, potentially lower-cost version (biosimilar) of an existing melanoma drug called nivolumab (Opdivo). It compared how the body processes the drugs, their effectiveness, and safety when combined with another drug (ipilimumab/Yervoy) in adults with advanced s…

This study tested whether adding an experimental drug called NT-I7 to an existing immunotherapy (atezolizumab) could help control advanced skin cancers. It focused on patients whose cancers had not responded to or had returned after similar treatments. The main goals were to find…

This study tested an experimental drug called DAY101 (tovorafenib) in people aged 12 and older with advanced solid tumors that had stopped responding to other treatments. The goal was to see if the drug could shrink or control tumors that have specific genetic changes. The trial …

This study tested whether a special surgical technique performed during lymph node removal could prevent lymphedema, a painful and chronic swelling of the arm. It involved 264 patients with breast cancer or melanoma who were having lymph nodes removed. Researchers compared standa…

This study tested whether a vaccine called POL-103A could safely prevent melanoma from returning in patients who had surgery to remove it. It involved 504 people with high-risk melanoma who had their tumors surgically removed. The trial compared the vaccine to a placebo to see if…

This study aimed to understand how high-dose radiation therapy affects the body's immune system in patients with liver, colorectal, skin, or kidney cancers. Researchers collected blood samples from 28 patients before, during, and after radiation treatment to measure immune cell c…

This study created a registry to learn about the long-term health and wellbeing of young adults who survived cancer. It aimed to measure their levels of anxiety, depression, social support, and financial stress over time. Participants completed online surveys every 6-12 months to…